Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults-Reference-Cited by-同舟云学术

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Published:2020-11-06 Issue:3 Volume:62 Page:620-629
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Couturier Marie-Anne¹,Thomas Xavier²,Raffoux Emmanuel³,Huguet Françoise⁴,Berthon Céline⁵,Simand Célestine⁶,Gallego-Hernanz Maria-Pilar⁷,Hicheri Yosr⁸,Hunault Berger Mathilde⁹,Saillard Colombe¹⁰,Leguay Thibaut¹¹,Loiseau Clémence¹²,Béné Marie-Christine¹³,Chevallier Patrice¹⁴

Affiliation:

1. Department of Hematology, Hôpital Morvan, CHRU Brest, Brest, France

2. Department of Hematology, Hôpital Lyon-Sud, Lyon, France

3. Department of hematology, APHP St-Louis, Paris, France

4. Department of Hematology, CHRU – Institut Universitaire de Cancer Toulouse – Oncopole, Toulouse, France

5. Department of Hematology, Hôpital Claude Huriez, CHRU Lille, Lille cedex, France

6. Department of Hematology, CHU de Hautepierre, Strasbourg, France

7. Department of Hematology, CHU La Miletrie, Poitiers, France

8. Department of Hematology, Hôpital Saint Eloi, CHRU Montpellier, Montpellier, France

9. Department of Hematology, CHRU Angers, Angers, France

10. Department of Hematology, Institut Paoli Calmettes, Marseille, France

11. Department of Hematology, Hôpital Haut-Leveque, CHU Bordeaux, Bordeaux, France

12. Department of Hematology Oncology, CH de Versailles, Hôpital André Mignot, Le Chesnay, France

13. Department of Hematology/Biology, CHU Nantes, Nantes, France

14. Department of Hematology, CHU Nantes, Nantes, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1844198

Reference35 articles.

1. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

2. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

3. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

4. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

2. Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia;Frontiers in Pharmacology;2023-11-16

3. A pilot study of implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia;Scientific Reports;2023-10-05

4. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review;Leukemia & Lymphoma;2023-08

5. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison;Advances in Therapy;2023-05-19